CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $262,355 | -7.4% | 5,780 | +14.6% | 0.02% | -5.9% |
| Q2 2023 | $283,227 | -33.5% | 5,045 | -46.4% | 0.02% | -41.4% |
| Q1 2023 | $425,660 | +56.7% | 9,411 | +40.9% | 0.03% | +45.0% |
| Q4 2022 | $271,583 | -30.4% | 6,681 | +11.8% | 0.02% | -31.0% |
| Q3 2022 | $390,000 | -12.0% | 5,974 | -18.0% | 0.03% | -9.4% |
| Q2 2022 | $443,000 | -48.9% | 7,289 | -47.2% | 0.03% | -34.7% |
| Q1 2022 | $867,000 | -2.6% | 13,803 | +17.5% | 0.05% | -2.0% |
| Q4 2021 | $890,000 | +27.0% | 11,747 | +87.7% | 0.05% | +8.7% |
| Q3 2021 | $701,000 | +16.4% | 6,259 | +68.4% | 0.05% | +9.5% |
| Q2 2021 | $602,000 | +89.3% | 3,716 | +42.3% | 0.04% | +68.0% |
| Q1 2021 | $318,000 | – | 2,611 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |